Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraCal PT vs MTA Pulpotomy in Primary Molars
NCT04617600Unknown
- Sponsor
- Cairo University
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Implantable Devices
01
Overview
Randomised trial of TheraCal in reversible pulpitis (2 arms), sponsored by Cairo University. Primary endpoints: Survival rate (Absence of spontaneous pain) at 6 months and Survival rate (Absence of swelling) at 6 months. Status: unknown.
02
Drugs
TheraCal
03
Conditions
reversible pulpitis
Beyond the preview
Go deeper on NCT04617600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617600.